27932982|t|Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1- Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention
27932982|a|The impact of pharmacogenetic variants of cytochrome P450 2C19 (CYP2C19) on clopidogrel -mediated effects on platelet inhibition, inflammatory response and endothelial function, as well as risk of major adverse cardiovascular events (MACE), in coronary heart patients undergoing percutaneous coronary intervention (PCI) was investigated. To this end, we assessed the residual platelet aggregation rate (RPA), maximal aggregation rate (MAR) and plasma levels of sCD40L, sP-selectin, MMP-9, sVCAM-1 and sE-selectin after 24 h of PCI in 559 patients treated with clopidogrel and followed up for 1 year for evidence of MACE. CYP2C19(*)2 and (*)3 variants were identified using a clopidogrel -sensitive gene detection kit. Our results showed higher RPA and MAR as well as increased sE-selectin, sCD40L, sP-selectin, MMP-9, and sVCAM-1 levels in CYP2C19 intermediate metabolizer (IM, CYP2C19(*)1 / (*)2, or (*)1 / (*)3), poor metabolizer (PM, CYP2C19(*)2 / (*)2, (*)2 / (*)3, or (*)3 / (*)3) and combined IM+PM groups, relative to those in extensive metabolizers (EM, CYP2C19(*)1 /(*)1). In total, 519 patients completed 1 year of follow-up, among which 69 (13.3%) experienced MACE. The risk of MACE in CYP2C19 IM+PM patients was 2.664 times higher than that in CYP2C19 EM patients (OR = 2.664 (1.397-5.193), P = 0.004). The data suggest that CYP2C19(*)2 and (*)3 variants modulate the drug efficacy of clopidogrel in coronary heart patients undergoing PCI and further enhance the risk of MACE. Accordingly, CYP2C19 pharmacogenetic profiling may be beneficial for coronary heart patients undergoing PCI to predict the efficacy of treatment with clopidogrel. We propose that IM and PM patients should benefit from treatment with higher clopidogrel doses to improve efficacy and reduce the incidence of MACE.
27932982	0	6	Impact	T080	C4049986
27932982	10	17	CYP2C19	T028	C1332828
27932982	18	26	Variants	T028	C0678941
27932982	30	47	Clinical Efficacy	T080	C3850123
27932982	51	62	Clopidogrel	T109,T121	C0070166
27932982	70	74	Year	T079	C0439234
27932982	75	92	Clinical Outcomes	T080	C0085415
27932982	96	119	Coronary Heart Patients	T101	C0741926
27932982	131	165	Percutaneous Coronary Intervention	T061	C1532338
27932982	170	176	impact	T080	C4049986
27932982	180	204	pharmacogenetic variants	T045	C4277630
27932982	208	228	cytochrome P450 2C19	T116,T126	C0960580
27932982	230	237	CYP2C19	T116,T126	C0960580
27932982	242	253	clopidogrel	T109,T121	C0070166
27932982	275	294	platelet inhibition	T049	C0302106
27932982	296	317	inflammatory response	T046	C1155266
27932982	322	342	endothelial function	T059	C3694812
27932982	355	359	risk	T078	C0035647
27932982	363	398	major adverse cardiovascular events	T047	C1385306
27932982	400	404	MACE	T047	C1385306
27932982	410	433	coronary heart patients	T101	C0741926
27932982	445	479	percutaneous coronary intervention	T061	C1532338
27932982	481	484	PCI	T061	C1532338
27932982	533	567	residual platelet aggregation rate	T059	C0920267
27932982	569	572	RPA	T059	C0920267
27932982	575	599	maximal aggregation rate	T081	C1521828
27932982	601	604	MAR	T081	C1521828
27932982	610	623	plasma levels	T059	C0427425
27932982	627	633	sCD40L	T059	C2825885
27932982	635	646	sP-selectin	T059	C3890352
27932982	648	653	MMP-9	T116,T126	C0165519
27932982	655	662	sVCAM-1	T116,T129	C0078056
27932982	667	678	sE-selectin	T059	C3890402
27932982	693	696	PCI	T061	C1532338
27932982	704	712	patients	T101	C0030705
27932982	713	725	treated with	T061	C0332293
27932982	726	737	clopidogrel	T109,T121	C0070166
27932982	742	753	followed up	T058	C1522577
27932982	760	764	year	T079	C0439234
27932982	769	777	evidence	T078	C3887511
27932982	781	785	MACE	T047	C1385306
27932982	787	798	CYP2C19(*)2	T028	C1707181
27932982	803	807	(*)3	T028	C1707182
27932982	808	816	variants	T028	C0678941
27932982	822	832	identified	T080	C0205396
27932982	841	852	clopidogrel	T109,T121	C0070166
27932982	864	882	gene detection kit	T063	C1517481
27932982	888	895	results	T169	C1274040
27932982	903	913	higher RPA	T033	C0243095
27932982	918	921	MAR	T081	C1521828
27932982	933	942	increased	T081	C0205217
27932982	943	954	sE-selectin	T116,T129,T192	C0115305
27932982	956	962	sCD40L	T116,T129	C0167627
27932982	964	975	sP-selectin	T116,T129	C0134835
27932982	977	982	MMP-9	T116,T126	C0165519
27932982	988	995	sVCAM-1	T116,T129	C0078056
27932982	996	1002	levels	T080	C0441889
27932982	1006	1038	CYP2C19 intermediate metabolizer	T033	C3203684
27932982	1040	1042	IM	T033	C3845232
27932982	1044	1055	CYP2C19(*)1	T028	C1707180
27932982	1058	1062	(*)2	T028	C1707181
27932982	1067	1071	(*)1	T028	C1707180
27932982	1074	1078	(*)3	T028	C1707182
27932982	1081	1097	poor metabolizer	T033	C3845231
27932982	1099	1101	PM	T033	C3845231
27932982	1103	1114	CYP2C19(*)2	T028	C1707181
27932982	1117	1121	(*)2	T028	C1707181
27932982	1123	1127	(*)2	T028	C1707181
27932982	1130	1134	(*)3	T028	C1707182
27932982	1139	1143	(*)3	T028	C1707182
27932982	1146	1150	(*)3	T028	C1707182
27932982	1165	1177	IM+PM groups	T033	C0243095
27932982	1200	1222	extensive metabolizers	T033	C3845233
27932982	1224	1226	EM	T033	C3845233
27932982	1228	1239	CYP2C19(*)1	T028	C1707180
27932982	1240	1245	/(*)1	T028	C1707180
27932982	1262	1270	patients	T101	C0030705
27932982	1283	1287	year	T079	C0439234
27932982	1291	1300	follow-up	T058	C1522577
27932982	1337	1341	MACE	T047	C1385306
27932982	1347	1359	risk of MACE	T033	C1273410
27932982	1363	1376	CYP2C19 IM+PM	T033	C0243095
27932982	1377	1385	patients	T101	C0030705
27932982	1402	1408	higher	T080	C0205250
27932982	1422	1429	CYP2C19	T028	C1332828
27932982	1430	1432	EM	T033	C3845233
27932982	1433	1441	patients	T101	C0030705
27932982	1485	1489	data	T081	C0011001
27932982	1503	1514	CYP2C19(*)2	T028	C1707181
27932982	1519	1523	(*)3	T028	C1707182
27932982	1524	1532	variants	T028	C0678941
27932982	1546	1559	drug efficacy	T080	C0598333
27932982	1563	1574	clopidogrel	T109,T121	C0070166
27932982	1578	1601	coronary heart patients	T101	C0741926
27932982	1613	1616	PCI	T061	C1532338
27932982	1629	1636	enhance	T052	C2349975
27932982	1641	1653	risk of MACE	T033	C1273410
27932982	1668	1675	CYP2C19	T028	C1332828
27932982	1676	1701	pharmacogenetic profiling	T045	C4277630
27932982	1724	1747	coronary heart patients	T101	C0741926
27932982	1759	1762	PCI	T061	C1532338
27932982	1778	1799	efficacy of treatment	T080	C0087113
27932982	1805	1816	clopidogrel	T109,T121	C0070166
27932982	1834	1836	IM	T033	C3845232
27932982	1841	1843	PM	T033	C3845231
27932982	1844	1852	patients	T101	C0030705
27932982	1873	1882	treatment	T061	C0087111
27932982	1888	1894	higher	T080	C0205250
27932982	1895	1906	clopidogrel	T109,T121	C0070166
27932982	1916	1932	improve efficacy	T080	C0087113
27932982	1937	1943	reduce	T080	C0392756
27932982	1948	1957	incidence	T081	C0021149
27932982	1961	1965	MACE	T047	C1385306